What question did this study set out to answer?

This research aims to understand the mechanisms by which ADAM12 and ECM remodeling influence bladder cancer progression and immune response.

February 9, 2026Cellular SignallingOpen Access

ADAM12-programmed ECM-CAF remodeling activates PI3K–AKT and enforces an immune-excluded microenvironment to drive bladder cancer progression and therapy resistance

View Full Paper

Ask AI

Bookmark

Authors

Investigations reveal how ECM remodeling and immunity impacts bladder cancer progression and therapy resistance.

This research aims to understand the mechanisms by which ADAM12 and ECM remodeling influence bladder cancer progression and immune response.
Utilized single-cell transcriptome data analysis
Combined fibroblast GWAS data with TCGA and GEO data
Conducted multiplex immunofluorescence experiments
Performed in vitro and in vivo validation on cells and animals
Executed functional validation of ADAM12
ADAM12 associates with invasive bladder cancer and immune checkpoint upregulation
Inhibition of ADAM12 leads to reduced cancer cell proliferation and migration
Activation of the PI3K-AKT pathway correlates with increased cancer progression
ADAM12 overexpression enhances bladder cancer invasion and metastasis

Song et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark